Nigeria has emerged as a critical market for a groundbreaking $1 testing bundle targeting HIV, syphilis, and hepatitis B, according to a report by Premium Times. The initiative, developed by Premier Medical Corporation and Impact Nexus Africa, seeks to expand antenatal care services by integrating rapid diagnostic tests into existing healthcare systems. This move aligns with global efforts to eliminate mother-to-child transmission of these infections, particularly in low- and middle-income countries where access to comprehensive screening remains limited.
The testing package, launched in 2026, combines two rapid diagnostic tests under a single commercial offer. It includes the World Health Organization (WHO)-prequalified First Response HIV 1+2/Syphilis Combo Card Test and the First Response hepatitis B surface antigen (HBsAg) Card Test. These tests are designed to be used together, offering a cost-effective solution for antenatal care providers. The $1 price tag, excluding freight, taxes, and distribution costs, positions the bundle as a viable option for public and private sector purchasers in Nigeria and other African nations.
Impact Nexus Africa estimates that the package could generate $215 million in commodity savings across 74 low- and middle-income countries between 2026 and 2035. However, the projection is based on modeling and does not guarantee actual savings for individual countries. The analysis highlights that the bundle is 22% to 46% cheaper than procuring the tests separately, making it an attractive option for resource-constrained healthcare systems.
Nigeria’s inclusion in the list of high-volume markets underscores the country’s urgent need for improved hepatitis B screening. A 2026 analysis of Nigeria’s Demographic and Health Survey data revealed that while 72% of mothers attended antenatal care, only 12.3% were tested for hepatitis B during pregnancy. Earlier national data further emphasized the gap, with just 7.2% of 2.8 million pregnant women screened for the infection across 6,000 facilities offering prevention of mother-to-child transmission services.
The Federal Ministry of Health and Social Welfare has been prioritizing hepatitis B screening as part of its triple-elimination strategy. In 2025, the ministry announced plans to introduce free hepatitis B testing, treatment, and care for pregnant women who test positive. The new testing bundle could complement these efforts by providing a lower-cost alternative to expand screening through existing antenatal care infrastructure.
The initiative is designed to build on current antenatal care systems rather than requiring new platforms. This approach is critical in Nigeria, where healthcare resources are often stretched thin. By leveraging existing services, the bundle aims to increase screening rates without overburdening facilities. The WHO recommends testing pregnant women for HIV, syphilis, and hepatitis B at least once during pregnancy, but hepatitis B screening remains inconsistent across many regions.
Premier Medical Corporation and Impact Nexus Africa emphasized that the package’s affordability and efficiency could significantly reduce the burden of these infections. The companies project that the modelled rollout could identify HBsAg-positive pregnancies in 17.1 million women and avert 2.7 million infant hepatitis B infections between 2026 and 2035. However, these outcomes depend on factors such as screening uptake, local hepatitis B prevalence, and successful linkage to maternal and infant interventions.
Nigeria’s current hepatitis B screening rates highlight the potential impact of the bundle. With only 12.3% of pregnant women tested for the infection, the country faces a significant challenge in preventing mother-to-child transmission. The new testing package could address this gap by making screening more accessible and cost-effective, particularly in underserved areas.
The companies also noted that the bundle includes digital training and competency tools for healthcare workers, ensuring proper implementation. This aspect is crucial for maintaining the accuracy and reliability of test results. The $1 price point, combined with these support mechanisms, positions the bundle as a scalable solution for expanding screening programs.
Public health experts have welcomed the initiative, citing its potential to improve maternal and child health outcomes. Dr. Amina Yusuf, a Nigerian epidemiologist, stated, “This testing bundle could be a game-changer for Nigeria, where hepatitis B remains a silent epidemic. By integrating it into antenatal care, we can reach more women and reduce the risk of transmission to their children.”
The Federal Ministry of Health has not yet commented on the specific implications for Nigeria, but the initiative aligns with its broader goals of strengthening healthcare access. The ministry’s 2025 plan to offer free hepatitis B testing for pregnant women underscores the importance of cost-effective solutions like the new bundle.
Critics, however, caution that the success of the initiative depends on local implementation. Dr. Chukwuma Okoro, a public health researcher, noted, “While the package is promising, its effectiveness will hinge on how well it is adopted by states and healthcare providers. Without adequate training and infrastructure, the potential benefits may not be fully realized.”
The testing bundle’s availability to public and private sector purchasers in low- and middle-income countries is subject to national registration and procurement requirements. This means Nigeria’s healthcare system will need to navigate regulatory processes to integrate the package into its antenatal care framework.
The initiative also highlights the role of private-sector partnerships in addressing public health challenges. Premier Medical Corporation and Impact Nexus Africa have positioned themselves as key players in expanding access to diagnostic tools, particularly in regions with limited resources. Their collaboration reflects a growing trend of cross-sector efforts to improve healthcare outcomes.
As Nigeria continues to grapple with maternal and child health challenges, the new testing bundle offers a promising avenue for progress. By reducing costs and streamlining screening processes, the initiative could play a pivotal role in achieving the WHO’s goal of eliminating mother-to-child transmission of HIV, syphilis, and hepatitis B.
The success of the bundle will depend on sustained investment, political will, and community engagement. With the right support, Nigeria could set a precedent for other countries facing similar challenges, demonstrating how innovative solutions can drive meaningful change in public health.
The Federal Ministry of Health and Social Welfare has not yet provided a formal response to the initiative, but the potential for the testing bundle to enhance Nigeria’s healthcare landscape is evident. As the country moves forward, the focus will remain on ensuring that these tools reach the communities that need them most.